Per Karlén

4.4k total citations · 1 hit paper
46 papers, 3.1k citations indexed

About

Per Karlén is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Per Karlén has authored 46 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 24 papers in Epidemiology and 12 papers in Immunology. Recurrent topics in Per Karlén's work include Inflammatory Bowel Disease (39 papers), Microscopic Colitis (23 papers) and Liver Diseases and Immunity (8 papers). Per Karlén is often cited by papers focused on Inflammatory Bowel Disease (39 papers), Microscopic Colitis (23 papers) and Liver Diseases and Immunity (8 papers). Per Karlén collaborates with scholars based in Sweden, Denmark and United Kingdom. Per Karlén's co-authors include Robert Löfberg, Olle Broström, Johan Askling, Annika Lapidus, Erik Hertervig, Anders Magnuson, Ingalill Friis–Liby, M. Vilien, Hans Verbaan and Per M. Hellström and has published in prestigious journals such as The Lancet, Gastroenterology and PLoS ONE.

In The Last Decade

Per Karlén

46 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

2005 789 citations Gunnar Järnerot, Erik Hertervig et al. Gastroenterology profile →

Peers

Countries citing papers authored by Per Karlén

Since Specialization

Citations

This map shows the geographic impact of Per Karlén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Karlén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Karlén more than expected).

Fields of papers citing papers by Per Karlén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Karlén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Karlén. The network helps show where Per Karlén may publish in the future.

Co-authorship network of co-authors of Per Karlén

This figure shows the co-authorship network connecting the top 25 collaborators of Per Karlén. A scholar is included among the top collaborators of Per Karlén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Karlén. Per Karlén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study 2023 ·Therapeutic Advances in Gastroenterology ·(unknown), Carl Eriksson, (unknown), (unknown), Per Karlén, Olof Grip, Charlotte Söderman, Sven Almér, Erik Hertervig, Jan Marsal, (unknown), (unknown), Hans Strid, (unknown), Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson	4
2	Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG 2021 ·Scandinavian Journal of Gastroenterology ·Carl Eriksson, (unknown), Lina Vigren, (unknown), Anders Kärnell, Henrik Hjortswang, Daniel Bergemalm, (unknown), Sven Almér, Erik Hertervig, Per Karlén, Hans Strid, Jonas Halfvarson	6
3	Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study 2021 ·Therapeutic Advances in Gastroenterology ·Carl Eriksson, (unknown), (unknown), Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almér, Erik Hertervig, Jan Marsal, (unknown), (unknown), (unknown), Hans Strid, (unknown), (unknown), Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson, (unknown)	19
4	Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) 2018 ·Scandinavian Journal of Gastroenterology ·(unknown), Carl Eriksson, (unknown), (unknown), Susanna Jäghult, Jan Björk, Olof Grip, Henrik Hjortswang, Hans Strid, Per Karlén, Scott Montgomery, Jonas Halfvarson	8
5	Randomized, double-blind, placebo-controlled trial of CCR9-targeted leukapheresis treatment of ulcerative colitis patients 2016 ·Journal of Crohn s and Colitis ·Michael Eberhardson, Per Karlén, (unknown), Petra Jones, Annelie Lindberg, (unknown), Emma Lindh, Anders Odén, H. Glise, Ola Winqvist	10
6	Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients 2013 ·Alimentary Pharmacology & Therapeutics ·(unknown), Anders Magnuson, Jan Björk, Cecilia Benoni, Sven Almér, Ingalill Friis–Liby, Erik Hertervig, (unknown), Per Karlén, Anders Eriksson, G. Midhagen, Marie Carlson, Annika Lapidus, Jonas Halfvarson, Curt Tysk	64
7	A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease 2013 ·PLoS ONE ·Satish Keshav, Tomáš Vaňásek, Yaron Niv, Robert Petryka, (unknown), Mauro Bafutto, I Rácz, David J. Hetzel, Ole Haagen Nielsen, Séverine Vermeire, Walter Reinisch, Per Karlén, Stefan Schreiber, Thomas J. Schall, Pirow Bekker, (unknown)	110
8	Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study 2010 ·Alimentary Pharmacology & Therapeutics ·(unknown), G Järnerot, Erik Hertervig, Ingalill Friis–Liby, L. Blomquist, Per Karlén, Christer Grännö, M. Vilien, Morten B. Strøm, Hans Verbaan, Per M. Hellström, Anders Magnuson, Jonas Halfvarson, Curt Tysk	133
9	Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease 2010 ·BMC Gastroenterology ·Annelie Lindberg, Michael Eberhardson, Mats Karlsson, Per Karlén	33
10	Evidence for Immunosurveillance in Intestinal Premalignant Lesions 2010 ·Scandinavian Journal of Immunology ·Magnus K. Karlsson, K. Lindberg, Per Karlén, Åke Öst, Magnus Thörn, Ola Winqvist, Michael Eberhardson	17
11	Colitis-associated DNA aneuploidy and dysplasia in Crohnʼs disease and risk of colorectal cancer 2010 ·Inflammatory Bowel Diseases ·(unknown), Bernhard Tribukait, Åke Öst, Olle Broström, Per Karlén, Robert Löfberg, Johan Askling, Urban Sjöqvist	13
12	Decreasing Time-Trends of Colorectal Cancer in a Large Cohort of Patients With Inflammatory Bowel Disease 2009 ·Gastroenterology ·(unknown), Lena Brandt, Annika Lapidus, Per Karlén, Olle Broström, Robert Löfberg, Anders Ekbom, Johan Askling	195
13	Colectomy after rescue therapy for intravenous-steroid resistant acute ulcerative colitis : a 3-year follow-up study of the Swedish-Danish infliximab/placebo trial 2008 ·Gut ·Anders Gustavsson, Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby, L. Blomquist, Per Karlén, Christer Grännö, M. Vilien, (unknown), Hans Verbaan, Per M. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk	4
14	The sentinel node technique is useful for studies of intestinal immunology in inflammatory bowel disease patients 2008 ·European Journal of Gastroenterology & Hepatology ·Michael Eberhardson, K. Lindberg, Mats Karlsson, Per Karlén, Ola Winqvist, Magnus Thörn	5
15	A 2-year follow-up of the swedish-danish Infliximab/Placebo trial in steroid resistant acute ulcerative colitis 2007 ·Gastroenterology ·Anders Gustavsson, (unknown), Erik Hertervig, (unknown), Lars Blomquist, Per Karlén, Christer Grännö, M. Vilien, Magnus Ström, (unknown), Hans Verbaan, Per M. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk	14
16	Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia 2006 ·Scandinavian Journal of Gastroenterology ·Tryggve Ljung, Ole Østergaard Thomsen, Morten Vatn, Per Karlén, Lars Karlsen, Curt Tysk, (unknown), Anders Kilander, R. Gillberg, Olof Grip, Stefan Lindgren, Ragnar Befrits, Robert Löfberg	41
17	Family history as a risk factor for colorectal cancer in inflammatory bowel disease 2001 ·Gastroenterology ·Johan Askling, Paul W. Dickman, Anders Ekbom, Per Karlén, Olle Broström, Annika Lapidus, Robert Löfberg	320
18	Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study 1998 ·Gut ·Per Karlén, Dan Kornfeld, Olle Broström, Robert Löfberg, (unknown), Anders Ekbom	209
19	Colorectal cancer in colonic Crohn's disease-High frequency of DNA-aneuploidy 1996 ·Gut ·Robert Löfberg, Ragnar Befrits, (unknown), Per Karlén, Åke Öst, Carlos Rubio-Terrés, B. Tribukait, Paul Rutgeerts, Karel Geboes	1
20	Colonoscopic surveillance in long-standing total ulcerative colitis—A 15-year follow-up study 1990 ·Gastroenterology ·Robert Löfberg, Olle Broström, Per Karlén, Bernhard Tribukait, Åke Öst	159

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact